Results 211 to 220 of about 2,507,641 (307)

Dipyridamole as a Perioperatively Safe Aurora Kinase A Inhibitor for Neoadjuvant Therapy in Esophageal Squamous Cell Carcinoma. [PDF]

Onco Targets Ther
Song J.
europepmc   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Contrast-enhanced mammography in the setting of neoadjuvant therapy from a multidisciplinary perspective. [PDF]

Insights Imaging
Pires-Gonçalves L, Leal C, Guimarães-Santos A, Aguiar AT, Abreu M, Brito D, Henrique RM.   +6 more
europepmc   +1 more source

Neoadjuvant Therapy for Malignant Melanoma

This thesis explores the emerging role of neoadjuvant therapy in the management of resectable malignant melanoma. Neoadjuvant approaches using immune checkpoint inhibitors and targeted therapies - offer potential benefit such as early immune activation ...
Shoval, Shahaf
core  

Estimation of Subtype‐Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology‐Inspired Natural History Models

International Journal of Cancer, EarlyView.
ABSTRACT Breast cancer progression varies across molecular subtypes, influencing detection rates and prognosis. Differences in the proportion of interval cancers (PIC)—cancers detected symptomatically between scheduled screening rounds—have been observed across subtypes, likely reflecting heterogeneity in tumour growth dynamics. We applied a continuous‐
Letizia Orsini, Yuqi Zhang, Kamila Czene, Keith Humphreys   +3 more
wiley   +1 more source

Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. [PDF]

Ann Surg Oncol
McClelland PH, Satyadi MA, Johnson RP, Jacob R, Pan J, Rai J, Rai S, Sohal D, Olowokure O, Kharofa J, Wilson GC, Patel SH, Ahmad SA.   +12 more
europepmc   +1 more source

Pretreatment EBV‐DNA/TLG‐Based Risk Stratification Is Associated With Survival Outcomes in Nonmetastatic Nasopharyngeal Carcinoma: An Exploratory Study

International Journal of Cancer, EarlyView.
ABSTRACT Whether combining pretreatment plasma Epstein–Barr virus DNA (EBV‐DNA) with 18F‐FDG PET/CT‐derived total lesion glycolysis (TLG) improves prognostic stratification in nonmetastatic nasopharyngeal carcinoma (NPC) is unclear, particularly in nonendemic populations.
Mehmet Çağrı Duymaz, Ece Özkaya Duymaz, Nazlı Ünsal, Recep Bekiş, Büşra Tozduman, Özgür Appak, Ayşe Demiral, Oğuz Çetinayak   +7 more
wiley   +1 more source

The role of serum adipokines in predicting response to neoadjuvant therapy in patients with locally advanced rectal cancer. [PDF]

Rev Assoc Med Bras (1992)
Sevik HO, Akay O, Guler M, Demir A, Arikan S, Idiz UO, Sevinc MM, Ari A, Sakin A, Tatar C.   +9 more
europepmc   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka, Johann Kornowski, Elena Laakmann, Barbara Schmalfeldt, Tim Zell, Glenn Geidel, Christoffer Gebhardt, Pia Roser, Volkmar Müller, Julian Kött   +9 more
wiley   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source